KYMR · Kymera Therapeutics Inc
United States · RS rating 69 · As of 2026-10-14
| Price | 106.83 USD |
|---|---|
| 1-day change | +0.1% |
| RS rating (overall / 1M / 3M / 12M) | 69 / 35 / 40 / 93 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 36 / 37 / 15 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -3.2% |
| Sales growth Q/Q | +3.8% |
| Distance from 52-week high | +16.1% |
| Market cap (USD) | $7.1B |